CpG oligodeoxynucleotide ligand potentiates the activity of the pVAX1-Sj26GST

Lu, Jun; Jiang, Shan; Song, Yajuan; Deng, Yun; Ma, Shuai; Chao-pin, LI

doi:10.3892/br.2013.99

Cited by 5 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there was a positive report on the use of this adjuvant in 2005 for a DNA-based HIV vaccine [ 42 ], the only other HIV vaccine tested using this adjuvant is one based on a peptide [ 43 ]. The use of this adjuvant has been reported to have improved immune responses to other DNA vaccines, for example against schistosomiasis [ 49 ], toxoplasmosis [ 50 ], atherosclerosis [ 51 ], various bacteria [ 52 , 53 ], and tumors [ 54 , 55 , 56 ].…”

Section: Discussionmentioning

confidence: 99%

Needle-Free Devices and CpG-Adjuvanted DNA Improve Anti-HIV Antibody Responses of Both DNA and Modified Vaccinia Ankara-Vectored Candidate Vaccines

et al. 2023

View full text Add to dashboard Cite

The combination of mosaic Gag and CAP256 envelope in an HIV vaccine regimen comprising DNA prime and modified vaccinia Ankara (MVA) boost followed by protein boost has previously been shown to generate robust autologous Tier 2 neutralizing antibodies (nAbs) in rabbits. Further refinements of this strategy have been investigated to improve antibody responses. The delivery of both DNA and recombinant MVA vaccines with a needle-free device was compared to delivery by injection, and the effect of formulating the DNA vaccine with adjuvant CpG ODN 1826 was determined. The Pharmajet Stratis® needle-free injection device (PharmaJet, Golden, CO, USA) improved binding antibody responses to the DNA vaccine as well as both binding and neutralizing antibody responses to the MVA vaccines. Formulation of the DNA vaccines with CpG adjuvant further improved the antibody responses. A shortened vaccination regimen of a single DNA inoculation followed by a single MVA inoculation did not elicit Tier 1B nor Tier 2 neutralization responses as produced by the two DNA, followed by two MVA vaccination regimen. This study showed the immunogenicity of HIV DNA and MVA vaccines administered in a DDMM regimen could be improved using the PharmaJet Stratis needle-free injection device and formulation of the DNA vaccines with CpG adjuvant.

show abstract

Section: Discussionmentioning

confidence: 99%

Needle-Free Devices and CpG-Adjuvanted DNA Improve Anti-HIV Antibody Responses of Both DNA and Modified Vaccinia Ankara-Vectored Candidate Vaccines

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The glucopyranosyl lipid A (GLA) formulated in aluminum (GLA-Alum), a TLR4 ligand, combined with sm-p80 vaccine could induce balanced Th (Th1, Th2 and Th17) immune responses and significant sm-p80specific antibodies production in vaccinated animals but did not maximize the immunogenicity and efficacity of the vaccine as expected (Zhang et al, 2018). Investigation on the ligands of TLR7/8 (R848) and TLR9 (CpG oligonucleotide) revealed that both of them block Treg immunosuppressive function and upregulate the production of TNF-a, IFN-g, and several interleukins in vitro (Lu et al, 2013;Wang et al, 2013). Interestingly, in vivo experiment revealed that the combination of R848 and CpG with the DNA vaccine 26-kDa glutathione Stransferase of S. japonicum (pVAX1-Sj26GST) induces a significant protective immunity in animal model, suggesting that the combination of multiple TLR ligands may be targeted as a promising new approach for the design of Schistosoma vaccines (Wang et al, 2012;Wang et al, 2013).…”

Section: Harnessing Innate Immune Signaling In Vaccine Research and S...mentioning

confidence: 99%

Pattern recognition receptor signaling and innate immune responses to schistosome infection

Dibo

Liu

Chang

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Schistosomiasis remains to be a significant public health problem in tropical and subtropical regions. Despite remarkable progress that has been made in the control of the disease over the past decades, its elimination remains a daunting challenge in many countries. This disease is an inflammatory response-driven, and the positive outcome after infection depends on the regulation of immune responses that efficiently clear worms and allow protective immunity to develop. The innate immune responses play a critical role in host defense against schistosome infection and pathogenesis. Initial pro-inflammatory responses are essential for clearing invading parasites by promoting appropriate cell-mediated and humoral immunity. However, elevated and prolonged inflammatory responses against the eggs trapped in the host tissues contribute to disease progression. A better understanding of the molecular mechanisms of innate immune responses is important for developing effective therapies and vaccines. Here, we update the recent advances in the definitive host innate immune response to schistosome infection, especially highlighting the critical roles of pattern recognition receptors and cytokines. The considerations for further research are also provided.

show abstract

“…A combined CpG/Poly (I:C) adjuvant enhanced the immunogenicity in mice of a DNA vaccine against eastern equine encephalitis virus [62]. Similarly, the TLR9 ligand, CpG, has been successfully used to enhance immunogenicity of DNA vaccines [62,[66][67][68]. RIG-I-like receptors are important intracellular proteins that sense double stranded RNA.…”

Section: Ligands Of Pattern Recognition Receptorsmentioning

confidence: 99%

Molecular mechanisms for enhanced DNA vaccine immunogenicity

Petrovsky

2015

Expert Review of Vaccines

263

252

View full text Add to dashboard Cite

Summary In the two decades since their initial discovery, DNA vaccines technologies have come a long way. Unfortunately, when applied to human subjects inadequate immunogenicity is still the biggest challenge for practical DNA vaccine use. Many different strategies have been tested in preclinical models to address this problem, including novel plasmid vectors and codon optimization to enhance antigen expression, new gene transfection systems or electroporation to increase delivery efficiency, protein or live virus vector boosting regimens to maximise immune stimulation, and formulation of DNA vaccines with traditional or molecular adjuvants. Better understanding of the mechanisms of action of DNA vaccines has also enabled better use of the intrinsic host response to DNA to improve vaccine immunogenicity. This review summarizes recent advances in DNA vaccine technologies and related intracellular events and how these might impact on future directions of DNA vaccine development.

show abstract

CpG oligodeoxynucleotide ligand potentiates the activity of the pVAX1-Sj26GST

Abstract: Abstract. Schistosomiasis is considered one of the most important neglected tropical diseases and remains a major public health problem in endemic countries. Toll-like receptor (TLR) ligands have been investigated as potential vaccine adjuvants for tumor and virus immunotherapy.

Cited by 5 publications

References 29 publications

Needle-Free Devices and CpG-Adjuvanted DNA Improve Anti-HIV Antibody Responses of Both DNA and Modified Vaccinia Ankara-Vectored Candidate Vaccines

Needle-Free Devices and CpG-Adjuvanted DNA Improve Anti-HIV Antibody Responses of Both DNA and Modified Vaccinia Ankara-Vectored Candidate Vaccines

Pattern recognition receptor signaling and innate immune responses to schistosome infection

Molecular mechanisms for enhanced DNA vaccine immunogenicity

Contact Info

Product

Resources

About